{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:50:18Z","timestamp":1761756618470,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"DOI":"10.7759\/cureus.95684","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:46:46Z","timestamp":1761756406000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient Characteristics and Reasons for Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Retrospective Cohort From a Large Urban HIV Clinic"],"prefix":"10.7759","author":[{"given":"Hao","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavya","family":"Manchukonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Simoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Hamlyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan J","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Kinloch-de Loes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. HIV and AIDS. (2025). Accessed. September 2, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng A","year":"2015","unstructured":"Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015, 79:182-94. 10.1111\/bcp.12403","journal-title":"Br J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1086\/597290","article-title":"Raltegravir: the first HIV type 1 integrase inhibitor","volume":"48","author":"Hicks C","year":"2009","unstructured":"Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009, 48:931-9. 10.1086\/597290","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao AV","year":"2022","unstructured":"Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022, 19:22. 10.1186\/s12977-022-00608-1","journal-title":"Retrovirology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12119","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)","volume":"15 Suppl 1","author":"Williams I","year":"2014","unstructured":"Williams I, Churchill D, Anderson J, et al.. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med. 2014, 15 Suppl 1:1-85. 10.1111\/hiv.12119","journal-title":"HIV Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12426","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015","volume":"17 Suppl 4","author":"Churchill D","year":"2016","unstructured":"Churchill D, Waters L, Ahmed N, et al.. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016, 17 Suppl 4:s2-s104. 10.1111\/hiv.12426","journal-title":"HIV Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"Gandhi RT","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al.. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2025, 333:609-28. 10.1001\/jama.2024.24543","journal-title":"JAMA"},{"key":"ref8","unstructured":"Initial Regimens. ART-na\u00efve Adults. (2025). Accessed: September 3, 2025: https:\/\/eacs.sanfordguide.com\/eacs-part1\/art\/eacs-initial-regimens-arv-naive-adults."},{"key":"ref9","unstructured":"BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2025 interim update). (2022). Accessed. September 3, 2025: https:\/\/bhiva.org\/wp-content\/uploads\/2024\/10\/BHIVA-guidelines-on-antiretroviral-treatment-for-adults-living-with-HIV-...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant J","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al.. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017, 390:2063-72. 10.1016\/S0140-6736(17)32299-7","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax PE","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al.. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017, 390:2073-82. 10.1016\/S0140-6736(17)32340-1","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina JM","year":"2018","unstructured":"Molina JM, Ward D, Brar I, et al.. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018, 5:e357-65. 10.1016\/S2352-3018(18)30092-4","journal-title":"Lancet HIV"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar ES","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, et al.. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018, 5:e347-56. 10.1016\/S2352-3018(18)30091-2","journal-title":"Lancet HIV"},{"key":"ref14","unstructured":"Royal Free HIV Cohort Study. (2025). Accessed. September 4, 2025: https:\/\/www.ucl.ac.uk\/population-health-sciences\/royal-free-hiv-cohort-study."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans With HIV-1: a randomized phase 3b, multicenter, open-label study","volume":"88","author":"Hagins D","year":"2021","unstructured":"Hagins D, Kumar P, Saag M, et al.. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans With HIV-1: a randomized phase 3b, multicenter, open-label study. J Acquir Immune Defic Syndr. 2021, 88:86-95. 10.1097\/QAI.0000000000002731","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002789","article-title":"Brief report: efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in females living with HIV: an integrated analysis of 5 trials","volume":"88","author":"Orkin C","year":"2021","unstructured":"Orkin C, Ajana F, Kityo C, et al.. Brief report: efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in females living with HIV: an integrated analysis of 5 trials. J Acquir Immune Defic Syndr. 2021, 88:393-8. 10.1097\/QAI.0000000000002789","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010076","article-title":"Switching to a bictegravir single tablet regimen in elderly people living with HIV-1: data analysis from the BICTEL cohort","volume":"12","author":"Lazzaro A","year":"2021","unstructured":"Lazzaro A, Cacciola EG, Borrazzo C, et al.. Switching to a bictegravir single tablet regimen in elderly people living with HIV-1: data analysis from the BICTEL cohort. Diagnostics (Basel). 2021, 12:76. 10.3390\/diagnostics12010076","journal-title":"Diagnostics (Basel)"},{"key":"ref18","unstructured":"\u200cNational procurement for antiretrovirals for HIV treatment and prevention. (2025). Accessed. September 4, 2025: https:\/\/bhiva.org\/wp-content\/uploads\/2024\/10\/National-procurement-for-antiretrovirals-for-HIV-treatment-and-preventio...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2239661","article-title":"Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims","volume":"39","author":"Tse J","year":"2023","unstructured":"Tse J, Prajapati G, Zhao X, Near AM, Kumar PN. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims. Curr Med Res Opin. 2023, 39:1237-46. 10.1080\/03007995.2023.2239661","journal-title":"Curr Med Res Opin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy505","article-title":"Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age \u226550 years: final 96-week results of the NEAT022 study","volume":"68","author":"Gatell JM","year":"2019","unstructured":"Gatell JM, Assoumou L, Moyle G, et al.. Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age \u226550 years: final 96-week results of the NEAT022 study. Clin Infect Dis. 2019, 68:597-606. 10.1093\/cid\/ciy505","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax PE","year":"2022","unstructured":"Sax PE, Andreatta K, Molina JM, et al.. High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I. AIDS. 2022, 36:1511-20. 10.1097\/QAD.0000000000003244","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01153-y","article-title":"Efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) after a viremic event: a pooled analysis of studies in people with HIV","volume":"14","author":"Pozniak A","year":"2025","unstructured":"Pozniak A, Orkin C, Yazdanpanah Y, et al.. Efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) after a viremic event: a pooled analysis of studies in people with HIV. Infect Dis Ther. 2025, 14:1201-17. 10.1007\/s40121-025-01153-y","journal-title":"Infect Dis Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417728207","article-title":"Reasons for switching ART: Comparison of data collected in 2012-2013 and 2014-2015 in Florence, Italy","volume":"29","author":"Fusco FM","year":"2018","unstructured":"Fusco FM, Burla MC, Degli Esposti A, Pierotti P, Rabatti L, Vichi F. Reasons for switching ART: Comparison of data collected in 2012-2013 and 2014-2015 in Florence, Italy. Int J STD AIDS. 2018, 29:392-5. 10.1177\/0956462417728207","journal-title":"Int J STD AIDS"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf137","article-title":"Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy","volume":"80","author":"Cozzi-Lepri A","year":"2025","unstructured":"Cozzi-Lepri A, Tavelli A, Taramasso L, et al.. Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy. J Antimicrob Chemother. 2025, 80:1849-59. 10.1093\/jac\/dkaf137","journal-title":"J Antimicrob Chemother"},{"key":"ref25","unstructured":"EMA. Biktarvy - European Medicines Agency. (2025). Accessed: September 23, 2025: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/biktarvy."},{"key":"ref26","unstructured":"NHS England. Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents. (2025). Accessed: September 23, 2025: https:\/\/www.england.nhs.uk\/publication\/tenofovir-alafenamide-for-treatment-of-hiv-1-in-adults-and-adolescents\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425187-patient-characteristics-and-reasons-for-switching-to-bictegraviremtricitabinetenofovir-alafenamide-a-retrospective-cohort-from-a-large-urban-hiv-clinic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:46:49Z","timestamp":1761756409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425187-patient-characteristics-and-reasons-for-switching-to-bictegraviremtricitabinetenofovir-alafenamide-a-retrospective-cohort-from-a-large-urban-hiv-clinic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.95684","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}